$ISRG
INTUITIVE SURGICAL INC

2012 Q2 Form 10-Q Financial Statement

#000119312512309316 Filed on July 23, 2012

View on sec.gov

Income Statement

Concept 2012 Q2 2011 Q2
Revenue $536.5M $425.7M
YoY Change 26.03% 21.39%
Cost Of Revenue $150.1M $119.1M
YoY Change 26.03% 26.84%
Gross Profit $386.4M $306.6M
YoY Change 26.03% 19.39%
Gross Profit Margin 72.02% 72.02%
Selling, General & Admin $120.9M $106.5M
YoY Change 13.52% 20.2%
% of Gross Profit 31.29% 34.74%
Research & Development $40.20M $32.00M
YoY Change 25.63% 29.03%
% of Gross Profit 10.4% 10.44%
Depreciation & Amortization $13.90M $11.20M
YoY Change 24.11% 14.29%
% of Gross Profit 3.6% 3.65%
Operating Expenses $161.1M $138.5M
YoY Change 16.32% 18.27%
Operating Profit $225.3M $168.1M
YoY Change 34.03% 20.33%
Interest Expense $4.000M $4.100M
YoY Change -2.44% -8.89%
% of Operating Profit 1.78% 2.44%
Other Income/Expense, Net $4.000M $4.100M
YoY Change -2.44%
Pretax Income $229.3M $172.2M
YoY Change 33.16% 19.42%
Income Tax $74.40M $54.80M
% Of Pretax Income 32.45% 31.82%
Net Earnings $154.9M $117.4M
YoY Change 31.94% 32.36%
Net Earnings / Revenue 28.87% 27.58%
Basic Earnings Per Share $3.88 $2.99
Diluted Earnings Per Share $3.75 $2.91
COMMON SHARES
Basic Shares Outstanding 39.90M shares 39.20M shares
Diluted Shares Outstanding 41.30M shares 40.30M shares

Balance Sheet

Concept 2012 Q2 2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.213B $994.0M
YoY Change 22.03% 2.69%
Cash & Equivalents $484.4M $382.0M
Short-Term Investments $728.0M $612.0M
Other Short-Term Assets $48.00M $21.00M
YoY Change 128.57% -22.22%
Inventory $119.4M $100.0M
Prepaid Expenses
Receivables $323.2M $250.0M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.703B $1.365B
YoY Change 24.78% 7.99%
LONG-TERM ASSETS
Property, Plant & Equipment $216.1M $194.0M
YoY Change 11.39% 34.72%
Goodwill $138.1M
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.419B $828.0M
YoY Change 71.38% 33.55%
Other Assets $75.00M $77.00M
YoY Change -2.6% 42.59%
Total Long-Term Assets $1.923B $1.285B
YoY Change 49.63% 31.26%
TOTAL ASSETS
Total Short-Term Assets $1.703B $1.365B
Total Long-Term Assets $1.923B $1.285B
Total Assets $3.626B $2.650B
YoY Change 36.83% 18.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $54.60M $38.00M
YoY Change 43.68% -9.52%
Accrued Expenses $124.0M $102.0M
YoY Change 21.57% 8.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $346.8M $274.0M
YoY Change 26.57% 12.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $96.90M $87.00M
YoY Change 11.38% 16.0%
Total Long-Term Liabilities $96.90M $87.00M
YoY Change 11.38% 16.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $346.8M $274.0M
Total Long-Term Liabilities $96.90M $87.00M
Total Liabilities $443.7M $361.0M
YoY Change 22.91% 13.17%
SHAREHOLDERS EQUITY
Retained Earnings $1.186B
YoY Change
Common Stock $1.993B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.182B $2.289B
YoY Change
Total Liabilities & Shareholders Equity $3.626B $2.650B
YoY Change 36.83% 18.15%

Cashflow Statement

Concept 2012 Q2 2011 Q2
OPERATING ACTIVITIES
Net Income $154.9M $117.4M
YoY Change 31.94% 32.36%
Depreciation, Depletion And Amortization $13.90M $11.20M
YoY Change 24.11% 14.29%
Cash From Operating Activities $210.8M $200.9M
YoY Change 4.93% 14.47%
INVESTING ACTIVITIES
Capital Expenditures -$8.100M -$38.50M
YoY Change -78.96% 89.66%
Acquisitions
YoY Change
Other Investing Activities -$108.8M -$133.5M
YoY Change -18.5% 54.69%
Cash From Investing Activities -$116.9M -$172.0M
YoY Change -32.03% 61.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $15.20M $139.1M
YoY Change -89.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 64.90M -96.70M
YoY Change -167.11% -353.81%
NET CHANGE
Cash From Operating Activities 210.8M 200.9M
Cash From Investing Activities -116.9M -172.0M
Cash From Financing Activities 64.90M -96.70M
Net Change In Cash 158.8M -67.80M
YoY Change -334.22% -163.36%
FREE CASH FLOW
Cash From Operating Activities $210.8M $200.9M
Capital Expenditures -$8.100M -$38.50M
Free Cash Flow $218.9M $239.4M
YoY Change -8.56% 22.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q3 isrg Time Limit Given To Plaintiffs For Filling Amended Complaint
TimeLimitGivenToPlaintiffsForFillingAmendedComplaint
30 Day
CY2012Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39934128 shares
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
382000000
CY2012Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
40800000
CY2012Q2 us-gaap Goodwill
Goodwill
138100000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2300000 shares
CY2012Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
7400000
CY2012Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
49500000
CY2012Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1993000000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2400000 shares
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
3182400000
CY2012Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
2626600000
CY2012Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1418700000
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
2631200000
CY2012Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
74500000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
223.89
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39900000 shares
CY2012Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
92900000
CY2012Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
3300000
CY2012Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
728100000
CY2012Q2 us-gaap Liabilities
Liabilities
443700000
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
54600000
CY2012Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
97200000
CY2012Q2 us-gaap Notional Amount Of Foreign Currency Cash Flow Hedge Derivatives
NotionalAmountOfForeignCurrencyCashFlowHedgeDerivatives
6600000
CY2012Q2 us-gaap Notional Amount Of Foreign Currency Cash Flow Hedge Derivatives
NotionalAmountOfForeignCurrencyCashFlowHedgeDerivatives
34700000
CY2012Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
168200000
CY2012Q2 us-gaap Notional Amount Of Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
NotionalAmountOfForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-900000
CY2012Q2 us-gaap Notional Amount Of Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
NotionalAmountOfForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
21400000
CY2012Q2 us-gaap Notional Amount Of Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
NotionalAmountOfForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
5000000
CY2012Q2 us-gaap Notional Amount Of Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
NotionalAmountOfForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
5700000000
CY2012Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
96900000
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2012Q2 us-gaap Derivative Assets
DerivativeAssets
1200000
CY2012Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
74600000
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1185800000
CY2012Q2 us-gaap Assets
Assets
3626100000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
296.03
CY2012Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
323200000
CY2012Q2 us-gaap Inventory Net
InventoryNet
119400000
CY2012Q2 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
7500000
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3626100000
CY2012Q2 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
8800000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
484400000
CY2012Q2 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
2900000
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39900000 shares
CY2012Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3600000
CY2012Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
34300000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
346800000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4700000 shares
CY2012Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3400000
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Assets Current
AssetsCurrent
1703300000
CY2012Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
81800000
CY2012Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
216100000
CY2012Q2 isrg Available For Sale Securities Amortized Cost Excluding Equity Securities
AvailableForSaleSecuritiesAmortizedCostExcludingEquitySecurities
2573300000
CY2012Q2 isrg Available For Sale Securities Excluding Equity Securities
AvailableForSaleSecuritiesExcludingEquitySecurities
2577700000
CY2012Q2 isrg Intangible And Other Assets
IntangibleAndOtherAssets
75300000
CY2012Q2 isrg Stock Repurchase Program Commencement To Date Repurchased Value
StockRepurchaseProgramCommencementToDateRepurchasedValue
695700000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
279800000
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20900000
CY2011Q4 us-gaap Goodwill
Goodwill
116900000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1600000 shares
CY2011Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
6200000
CY2011Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
37500000
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1742800000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
2645600000
CY2011Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
2170700000
CY2011Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1142600000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2011Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
2171800000
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
83100000
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39300000 shares
CY2011Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
93800000
CY2011Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2500000
CY2011Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
563400000
CY2011Q4 us-gaap Liabilities
Liabilities
417500000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
45800000
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
98100000
CY2011Q4 us-gaap Notional Amount Of Foreign Currency Cash Flow Hedge Derivatives
NotionalAmountOfForeignCurrencyCashFlowHedgeDerivatives
0
CY2011Q4 us-gaap Notional Amount Of Foreign Currency Cash Flow Hedge Derivatives
NotionalAmountOfForeignCurrencyCashFlowHedgeDerivatives
0
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
154200000
CY2011Q4 us-gaap Notional Amount Of Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
NotionalAmountOfForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-1700000
CY2011Q4 us-gaap Notional Amount Of Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
NotionalAmountOfForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
1800000
CY2011Q4 us-gaap Notional Amount Of Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
NotionalAmountOfForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
35000000
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
96900000
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2011Q4 us-gaap Derivative Assets
DerivativeAssets
3500000
CY2011Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
69100000
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
901900000
CY2011Q4 us-gaap Assets
Assets
3063100000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
254.19
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
297900000
CY2011Q4 us-gaap Inventory Net
InventoryNet
112100000
CY2011Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
6400000
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3063100000
CY2011Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
7900000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
465800000
CY2011Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
5300000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39300000 shares
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
900000
CY2011Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
34800000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
320600000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4700000 shares
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1100000
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Assets Current
AssetsCurrent
1466300000
CY2011Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
74800000
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
197200000
CY2011Q4 isrg Intangible And Other Assets
IntangibleAndOtherAssets
71000000
us-gaap Operating Income Loss
OperatingIncomeLoss
316400000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
21700000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
682600000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1800000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
393100000
us-gaap Share Based Compensation
ShareBasedCompensation
66900000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.51
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
150700000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.320 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
306300000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-169800000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
8500000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
102200000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-9000000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
91200000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3100000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40200000 shares
us-gaap Sales Revenue Net
SalesRevenueNet
813800000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3500000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
325800000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.65
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
63400000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-35100000
us-gaap Cost Of Revenue
CostOfRevenue
228400000
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
400000 shares
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
45200000
us-gaap Operating Expenses
OperatingExpenses
269000000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
24400000
us-gaap Cost Of Services
CostOfServices
50100000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39200000 shares
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
6500000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
13300000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1000000 shares
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
us-gaap Cost Of Goods Sold
CostOfGoodsSold
178300000
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
131200000
us-gaap Depreciation
Depreciation
13800000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
725900000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
66900000
us-gaap Gross Profit
GrossProfit
585400000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
216200000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-10000000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
800000
us-gaap Tax Benefit From Stock Options Exercised1
TaxBenefitFromStockOptionsExercised1
21100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2200000 shares
us-gaap Net Income Loss
NetIncomeLoss
221500000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9400000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
24400000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3300000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
205600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
104300000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
800000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
222500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8700000
us-gaap Foreign Currency Cash Flow Hedge Gain Loss Reclassified To Earnings Net
ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet
-1600000
isrg Average Purchase Price Of Share Under Repurchase Program
AveragePurchasePriceOfShareUnderRepurchaseProgram
345150000
isrg Payments To Acquire Productive Assets And Buisness
PaymentsToAcquireProductiveAssetsAndBuisness
53200000
isrg Realized Gains Losses On Investments
RealizedGainsLossesOnInvestments
2400000
dei Trading Symbol
TradingSymbol
ISRG
dei Entity Registrant Name
EntityRegistrantName
INTUITIVE SURGICAL INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001035267
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Operating Income Loss
OperatingIncomeLoss
418600000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
21100000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
867500000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5400000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
324800000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
349.37
us-gaap Share Based Compensation
ShareBasedCompensation
67700000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
508.70
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.26
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-600000 shares
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
15200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
-100000 shares
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.300 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
383000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-532300000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
12900000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Other Share Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
100000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
219.52
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18600000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-8400000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
138500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4400000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41100000 shares
us-gaap Sales Revenue Net
SalesRevenueNet
1031700000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21900000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
426400000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.52
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>NOTE 1. DESCRIPTION OF BUSINESS</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Intuitive designs, manufactures and markets <i>da Vinci</i> Surgical Systems and related instruments and accessories, which taken together, are advanced surgical systems that the Company believes represent a new generation of surgery. The Company believes that this new generation of surgery, which the Company calls <i>da Vinci</i> Surgery, combines the benefits of minimally invasive surgery (MIS) for patients with the ease of use, precision and dexterity of open surgery. A <i>da Vinci</i> Surgical System consists of a surgeon&#x2019;s console, a patient-side cart and a high performance vision system. The <i>da Vinci</i> Surgical System translates a surgeon&#x2019;s natural hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions, or ports. The <i>da Vinci</i> Surgical System is designed to provide its operating surgeon with intuitive control, range of motion, fine tissue manipulation capability and 3-D, High-Definition (HD) vision while simultaneously allowing them to work through the small ports of MIS.</font></p> </div>
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
-700000 shares
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
168000000
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
-900000
us-gaap Cost Of Revenue
CostOfRevenue
289400000
us-gaap Stock Repurchase Program Authorized Amount
StockRepurchaseProgramAuthorizedAmount
1248700000
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
100000 shares
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
46600000
us-gaap Operating Expenses
OperatingExpenses
323700000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
44700000
us-gaap Cost Of Services
CostOfServices
54800000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39700000 shares
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2000000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5000000
us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount
553000000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1400000 shares
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
us-gaap Cost Of Goods Sold
CostOfGoodsSold
234600000
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
164200000
us-gaap Depreciation
Depreciation
15200000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1022900000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67700000
us-gaap Gross Profit
GrossProfit
742300000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
229400000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-15200000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6100000
us-gaap Tax Benefit From Stock Options Exercised1
TaxBenefitFromStockOptionsExercised1
44700000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
600000 shares
us-gaap Net Income Loss
NetIncomeLoss
298400000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7800000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
44700000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-600000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
245100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
700000 shares
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
128000000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-100000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
301100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12000000
isrg Average Purchase Price Of Share Under Repurchase Program
AveragePurchasePriceOfShareUnderRepurchaseProgram
523060000
isrg Options Authorized Shares Available For Grant
OptionsAuthorizedSharesAvailableForGrant
1300000 shares
isrg Payments To Acquire Productive Assets And Buisness
PaymentsToAcquireProductiveAssetsAndBuisness
63600000
CY2011Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
168100000
CY2011Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
11200000
CY2011Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
358100000
CY2011Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.91
CY2011Q2 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
139100000
CY2011Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.318 pure
CY2011Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40300000 shares
CY2011Q2 us-gaap Sales Revenue Net
SalesRevenueNet
425700000
CY2011Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
172200000
CY2011Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.99
CY2011Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32000000
CY2011Q2 us-gaap Cost Of Revenue
CostOfRevenue
119100000
CY2011Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
400000 shares
CY2011Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
23600000
CY2011Q2 us-gaap Operating Expenses
OperatingExpenses
138500000
CY2011Q2 us-gaap Cost Of Services
CostOfServices
25600000
CY2011Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39200000 shares
CY2011Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1100000 shares
CY2011Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2011Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
93500000
CY2011Q2 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
67600000
CY2011Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34800000
CY2011Q2 us-gaap Gross Profit
GrossProfit
306600000
CY2011Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2500000 shares
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
117400000
CY2011Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4100000
CY2011Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1000000
CY2011Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
106500000
CY2011Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54800000
CY2011Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
120700000
CY2011Q2 us-gaap Foreign Currency Cash Flow Hedge Gain Loss Reclassified To Earnings Net
ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet
-1000000
CY2011Q2 isrg Average Purchase Price Of Share Under Repurchase Program
AveragePurchasePriceOfShareUnderRepurchaseProgram
347120000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
225300000
CY2012Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
10100000
CY2012Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
453100000
CY2012Q2 us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
1900000
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.75
CY2012Q2 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
15200000
CY2012Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.324 pure
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41300000 shares
CY2012Q2 us-gaap Sales Revenue Net
SalesRevenueNet
536500000
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
229300000
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.88
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40200000
CY2012Q2 us-gaap Cost Of Revenue
CostOfRevenue
150100000
CY2012Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
100000 shares
CY2012Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
23200000
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
161100000
CY2012Q2 us-gaap Cost Of Services
CostOfServices
27200000
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39900000 shares
CY2012Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1400000 shares
CY2012Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2012Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
122900000
CY2012Q2 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
83400000
CY2012Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33300000
CY2012Q2 us-gaap Gross Profit
GrossProfit
386400000
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
700000 shares
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
154900000
CY2012Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000000
CY2012Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1100000
CY2012Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
120900000
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
74400000
CY2012Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
157000000
CY2012Q2 isrg Average Purchase Price Of Share Under Repurchase Program
AveragePurchasePriceOfShareUnderRepurchaseProgram
523060000

Files In Submission

Name View Source Status
0001193125-12-309316-index-headers.html Edgar Link pending
0001193125-12-309316-index.html Edgar Link pending
0001193125-12-309316.txt Edgar Link pending
0001193125-12-309316-xbrl.zip Edgar Link pending
d361804d10q.htm Edgar Link pending
d361804dex311.htm Edgar Link pending
d361804dex312.htm Edgar Link pending
d361804dex321.htm Edgar Link pending
d361804dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
g361804g23k75.jpg Edgar Link pending
isrg-20120630.xml Edgar Link completed
isrg-20120630.xsd Edgar Link pending
isrg-20120630_cal.xml Edgar Link unprocessable
isrg-20120630_def.xml Edgar Link unprocessable
isrg-20120630_lab.xml Edgar Link unprocessable
isrg-20120630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending